A study reveals that a rare pediatric liver cancer arises from multiple liver cancer cells that independently undergo tumor-type transitions into other tumor types.

Mayo Clinic researchers have developed a promising new way to deliver treatment directly to cholangiocarcinoma tumors, a rare and aggressive bile duct cancer with limited treatment options, using milk-derived nanoparticles that act like guided delivery vehicles. The findings, published in JHEP Reports, point to a potential targeted genetic therapy designed to attack cancer cells while sparing healthy tissue.

About The Study: This cross-sectional analysis found that delays in treatment initiation for early-onset colorectal cancer—often exceeding 90 days—were more common in all-urban populations and appeared to disproportionately affect young male, Asian or Pacific Islander, Black, or Hispanic patients. Although absolute differences in average treatment timing were modest, the focus in this study on clinically relevant delay thresholds (30, 60, and 90 days) is supported by recent meta-analytic literature. The consistency of these delays across sociodemographic groups challenges assumptions of uniformly timely access in urban settings.

Women are more likely to survive cancer than men but face a higher risk of serious and adverse side effects from treatment, according to a landmark international study from Adelaide University.

Published in the Journal of the National Cancer Institute (JNCI) and conducted in partnership with a international collaborators, the research identified consistent differences between male and female cancer patients in both survival and treatment toxicity.

Female patients had a 21% lower risk of death compared with male patients, yet a 12% higher risk of severe toxicities.